Following our previous update on September 26, 2024, we are pleased to provide an update on the latest developments regarding CANNORDIC A/S's upcoming IPO on the German Stock Exchange. As part of our preparations, 5,000,000 shares have been successfully digitalized and assigned the ISIN number: DK0063296751. VP Securities is managing this process and will initiate the shares once the CANNORDIC pre-sale begins.

Our Financial Advisor in Germany, in collaboration with our team, is finalizing the prospectus for the German market, keeping us on track for the planned IPO. The pre-sale of CANNORDIC shares will offer an exclusive opportunity for early investors to acquire shares before the IPO launch.

Upcoming Market Analysis for CS MEDICA
A draft analysis of CS MEDICA’s valuation in Germany is underway and expected to be finalized next week, with public release to follow. This will provide key insights into our dual listing and growth potential in the EU market.

Next Steps:
The next step is the pre-sale of CANNORDIC shares, offering an exclusive opportunity to acquire shares before the IPO. Simultaneously, we are progressing on the details necessary to initiate the corporate action regarding the distribution of CANNORDIC shares to CS MEDICA investors, as previously announced. The exact details of this distribution will be communicated once the timeline is finalized.

We will keep you updated on key milestones.

Lone Henriksen
CEO, CS MEDICA A/S

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA A/S, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.
 

CANNORDIC A/S, a subsidiary of CS MEDICA Group, is a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD. Our dedication to enhancing lives by integrating innovation, science, technology, and natural cannabis compounds positions it as a pioneer in the medical technology industry. The company ensures robust research, development, manufacturing, compliance, data insights, and commercialization processes.